conditions precedent would have been prescribed in the initial...

conditions precedent would have been prescribed in the initial collaboration documents, so I doubt they could just keep asking for details. Silviu seemed pretty certain that after this set of data that has been provided to Novartis that they'd be able to close it out.

I do echo your sentiment that Novartis are not likely to walk away, especially when that 70-80% of non-COVID ARDS patients that end up in hospital beds with ventilators are <65 years old. The fact that remestemcel-l has shown a significant survival benefit especially with those also treated with Dex... your are right, Novartis are licking their lips.

I also note when asked about when the Novartis update can be expected... Silvui has consistently referred to updating us on the "timeline of the collaboration", rather than a response along the lines of "whether or not the collaboration will go ahead". Subtle but if there was inherent doubt in his mind, I don't think he'd use that kind of wording.